跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 24,755 条关于
“CARES-310”
全部
24,755
临床试验
21,348
药物
1,520
机构
278
资讯
1,609
去年
Rivoceranib Plus Camrelizumab Shows Promise in First-Line HCC Treatment
去年
FDA Accepts Resubmission of NDA for Rivoceranib and Camrelizumab in Unresectable Hepatocellular Carcinoma
去年
FDA Accepts NDA Resubmission for Rivoceranib/Camrelizumab Combo in Unresectable HCC
去年
FDA Accepts Rivoceranib and Camrelizumab Combination for Liver Cancer
去年
FDA Accepts Resubmission of Rivoceranib and Camrelizumab for Liver Cancer
3年前
FDA Accepts NDA for Rivoceranib and Camrelizumab Combination in Unresectable Hepatocellular Carcinoma
2年前
Elevar Therapeutics Plans NDA Resubmission for Rivoceranib/Camrelizumab in Unresectable HCC After CRL
上个月
Elevar Therapeutics to Present Three Abstracts at ESMO 2026, Including Phase 2 THRIVE Trial of Rivoceranib in Thymic Tumors
2个月前
FDA Issues Complete Response Letter for Elevar's Rivoceranib-Camrelizumab Combination in First-Line HCC
3年前
Elevar Therapeutics Seeks FDA Approval for Rivoceranib and Camrelizumab Combination in Unresectable Hepatocellular Carcinoma
第 1 页,共 161 页
上一页
下一页